PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12082821-2	2002	STI571 (signal transduction inhibition number 571) is a potent and selective inhibitor of the BCR-ABL tyrosine kinase.	serum sodium transport inhibitor	0-6	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	94-101	
11495816-4	2001	Produced from the 2-phenylaminopyrimidine class, a novel synthetic inhibitor, identified as CGP57148 (STI571), inhibits tyrosine kinase activity of c-ABL, BCR-ABL, PDGF-R and c-kit at micromolar concentrations.	serum sodium transport inhibitor	102-108	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	148-153	
11495816-4	2001	Produced from the 2-phenylaminopyrimidine class, a novel synthetic inhibitor, identified as CGP57148 (STI571), inhibits tyrosine kinase activity of c-ABL, BCR-ABL, PDGF-R and c-kit at micromolar concentrations.	serum sodium transport inhibitor	102-108	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	155-162	
10523635-7	1999	Also, an ABL-specific tyrosine kinase inhibitor, CGP57148B (STI571), rapidly caused reexpression of SHIP, indicating that BCR/ABL directly, but reversibly, regulates the expression of SHIP protein.	serum sodium transport inhibitor	60-66	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	122-129	
11423669-1	2001	Therapeutic agent STI571 (signal transduction inhibitor number 571) is a rationally developed, potent, and selective inhibitor for abl tyrosine kinases, including bcr-abl, as well c-kit and the platelet-derived growth factor receptor tyrosine kinases.	serum sodium transport inhibitor	18-24	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	163-170